Rituximab does not adversely affect the stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 153(3): 211-4, 2009 Sep.
Article
de En
| MEDLINE
| ID: mdl-19851434
AIMS AND METHODS: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). RESULTS: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x10(6)/ kg in the non-R group and 7.81x10(6)/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x10(4)/kg) compared to the R group (76.6x10(4)/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x10(4)/kg) than the R patients (31.3x10(4)/kg; p = 0.001). CONCLUSIONS: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179).
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Lymphome B diffus à grandes cellules
/
Mobilisation de cellules souches hématopoïétiques
/
Transplantation de cellules souches
/
Anticorps monoclonaux
/
Antinéoplasiques
Type d'étude:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limites:
Humans
/
Middle aged
Langue:
En
Journal:
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Sujet du journal:
MEDICINA
Année:
2009
Type de document:
Article
Pays d'affiliation:
République tchèque
Pays de publication:
République tchèque